China
· Delayed Price · Currency is CNY Jiangsu Yahong Meditech Company Description
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally.
Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes.
In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer.
Further, the company develops APL-1401 to treat moderately to severely active ulcerative colitis; and ASN-1733 to treat acinetobacter baumannii infection.
Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.
| Country | China |
| Founded | 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 394 |
| CEO | Kevin Pan |
Contact Details
Address: Building B, Qiantan World Trade Center Shanghai, 200126 China | |
| Phone | 86 21 6858 3863 |
| Website | asieris.cn |
Stock Details
| Ticker Symbol | 688176 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005XW0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Pan | Founder, Chairman and Chief Executive Officer |
| Mingyuan Yang | Financial Manager, Director and Board Secretary |
| Chengfeng Zhuang | Deputy GM and Director |
| David Wilson Ph.D. | Senior Vice President of BD |
| Dr. Chen Yu | Senior Vice President of Biological Research, Drug Discovery Division and Head of Translational Medicine Research |
| Yang Zhao | Senior Vice President of Business Development |